Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
GLAXO
Mr. Bhushan Akshikar · Mumbai, India · 3,103 employees
₹2,626.40
▼-0.24%Glaxo is trading near its 52-week low despite strong profitability metrics, suggesting potential undervaluation amid modest revenue growth.
Exchange
NSI
Currency
INR
Day range
₹2,609.00 – ₹2,670.00
52-week range
₹2,088.10 – ₹3,200.00
Sector
Healthcare
Industry
Drug Manufacturers - General
AI investment rating
AI analysis75% confidence
The stock appears undervalued relative to its historical range and strong fundamentals, trading significantly below its 52-week high despite healthy margins and ROE.
17.9% below the 1-year high · trend down
Hedge-fund memo
Today
The stock is down marginally today but trading within its recent range near the lower end of its 52-week range.
This week
The stock has been trading in a narrow range this week, showing no significant directional movement.
This month
The stock has declined approximately 5% over the past month, underperforming the broader market.
Bull thesis
Bear thesis
News & sentiment
Neutral
5 headlines · 5 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| GLAXO | 444.93B | 43.00 | 49.11% | 34.42% | 2.10% |
| PFIZER | 217.54B | 29.60 | 17.16% | 35.25% | 6.30% |
| DRREDDY | 951.54B | 28.74 | 8.84% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Patent expiries on key products
Mitigation: Focus on developing new products and expanding in emerging markets with less generic competition
Regulatory hurdles in key markets
Mitigation: Diversify geographic footprint and invest in compliance infrastructure
Increased competition in generic segments
Mitigation: Strengthen branded portfolio and focus on high-margin specialty products
Business intelligence
Competitive moat
Strong brand recognition, extensive distribution network, and diversified therapeutic portfolio provide a durable competitive advantage in the pharmaceutical industry.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Positive updates on pipeline products
Earnings report showing revenue acceleration
Thesis builder
Bull case
Strong profitability and potential pipeline success could drive significant upside from current levels.
Base case
The stock may trade in a range as it balances modest revenue growth with strong margins.
Bear case
Slowing revenue growth and increased competition could pressure valuation multiples.
Time horizon
12-18 months
Est. CAGR
5-8%
Entry (qual.)
Current levels or on any further weakness towards 2200-2300
Exit (qual.)
Above 3000 or if revenue growth consistently falls below 1%
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how GLAXO fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain GLAXO for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
The stock appears attractive at current levels given its strong profitability and trading near 52-week lows, but investors should monitor revenue growth trends.
Eye For Film·2d ago·irrelevant to business outlook
Yahoo Finance Singapore·2d ago·strong earnings beat positive
10tv.com·2d ago·neutral earnings snapshot
Encyclopedia Britannica·5d ago·neutral company description
TradingView·5d ago·neutral revenue breakdown
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 4.25% |
| -5.60% |
| ABB | 1.55T | 99.73 | — | 11.50% | 0.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹2,609.00
Resistance (day/52w high)
₹2,670.00
Volume
59,537
Trend
down
RSI (14)
70
MACD
bullish
MA cross
death
50-day MA
₹2,344.90
200-day MA
₹2,443.10
vs 200-DMA
7.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.